PCA
SCPH

Peddock Capital Advisors’s scPharmaceuticals SCPH Stock Holding History

Peddock Capital Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100
Closed -$1K – 268
2018
Q1 		$1K Buy
+100
New +$1.34K ﹤0.01% 250

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Peddock Capital Advisors's SCPH Position: Q2 2018 in Review

Peddock Capital Advisors sold out of scPharmaceuticals (SCPH) in Q2 2018, closing a stake of 100 shares — an estimated $1K sold.

Peddock Capital Advisors first reported a position in SCPH in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 41 funds tracked by Wall St. Rank hold SCPH as of Q2 2018.

  • Peddock Capital Advisors reported no remaining scPharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Peddock Capital Advisors sold 100 scPharmaceuticals shares in Q2 2018, an estimated $1K.
  • Peddock Capital Advisors first reported a position in scPharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Peddock Capital Advisors's scPharmaceuticals position peaked at $1K in Q1 2018.
  • 41 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2018.

Based on Peddock Capital Advisors's 13F filing for Q2 2018, filed 3 Aug 2018.